)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Ironwood Pharmaceuticals (IRWD) investor relations material
Ironwood Pharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Reported net income of $23.6 million for Q2 2025, reversing a net loss of $0.9 million in Q2 2024; six-month net loss was $13.8 million compared to $5.0 million loss in the prior year period.
LINZESS U.S. net sales reached $248 million in Q2 2025, up 17% year-over-year, with 10% prescription demand growth.
Major restructuring in Q1 2025 reduced workforce by approximately 50%, primarily field-based sales, incurring $18.0 million in restructuring expenses for the six months.
Engaged Goldman Sachs to explore strategic alternatives, including potential transactions to maximize shareholder value.
Confirmatory Phase 3 trial design for apraglutide is being finalized, with FDA alignment planned for Q4 2025.
Financial highlights
Total revenue was $85.2 million in Q2 2025, down from $94.4 million year-over-year, mainly due to lower net profits from LINZESS sales and increased development costs for apraglutide.
GAAP net income was $23.6 million ($0.15 per share basic) in Q2 2025, compared to a net loss of $0.9 million in Q2 2024.
Adjusted EBITDA rose to $50.1 million from $36.5 million year-over-year.
Cash and cash equivalents stood at $92.9 million as of June 30, 2025.
Interest expense increased to $8.4 million in Q2 2025, up from $7.5 million in Q2 2024, due to higher Revolving Credit Facility balances.
Outlook and guidance
Full-year 2025 guidance maintained: LINZESS U.S. net sales of $800–$850 million, total revenue of $260–$290 million, and adjusted EBITDA above $105 million.
Cash, expected operating inflows, and borrowing capacity are projected to cover operating needs for at least the next twelve months.
High single-digit prescription demand growth expected, offset by price erosion from Medicare Part D redesign.
LINZESS partnership revenues with AbbVie expected to remain a significant revenue source; continued investment in linaclotide and apraglutide development anticipated.
A confirmatory Phase III trial for apraglutide is planned for 2026, pending FDA alignment.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ironwood Pharmaceuticals earnings date
Q3 20256 Nov, 2025
Next Ironwood Pharmaceuticals earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Ironwood Pharmaceuticals Inc is a gastrointestinal-focused healthcare company that develops and markets therapies for chronic digestive diseases. The company’s product portfolio includes treatments for irritable bowel syndrome and other gastrointestinal conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage